Fumarase deficiency (FMRD) is a rare autosomal recessive metabolic disorder. It results from a deficiency in fumarate hydratase (FH). Consequently, patients exhibit a broad Fumarase Deficiency spectrum of presentations. These range from severe early-onset encephalopathy to milder cognitive impairments. Recent research by Ting SL et al. provides a detailed look at this variability across different age groups.

Understanding the Fumarase Deficiency Spectrum

The study reviewed data from ten patients across three metabolic centers. Specifically, the cohort included seven females and three males. Interestingly, the median age at diagnosis was five years. However, the range was quite broad, from just one day to sixteen years. All patients exhibited developmental delay. Furthermore, learning difficulties were present in varying degrees of severity.

Diagnostic tools showed mixed results. For instance, elevated urinary fumarate was present in 70% of patients. Yet, this marker was inconsistent during repeat analysis. Additionally, half of the patients had neutropenia. Neuroimaging revealed abnormal findings in four cases. These results highlight the diagnostic conundrum clinicians face when managing such rare metabolic conditions.

Genetic Heterogeneity and Cancer Risks

Molecular analysis identified biallelic FH variants in nine patients. Five distinct variants were found, including four missense and one in-frame duplication. Notably, the c.410C>T variant was the most frequent. Furthermore, the c.1431_1433dupAAA p.(Lys477dup) variant was identified in patients with milder intellectual disabilities. This specific variant overlaps with classic FMRD features but remains distinct in its severity.

Crucially, the study emphasized the risk for carriers. Heterozygous carriers of certain FH variants are predisposed to hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Indeed, renal lesions were detected in two heterozygous fathers in this cohort. Therefore, the researchers suggest that all variants found in FMRD patients need independent clinical evaluation for HLRCC associations.

Frequently Asked Questions

Can urinary fumarate levels confirm a diagnosis within the Fumarase Deficiency spectrum?

While elevated urinary fumarate is a common sign, it is not always consistent. The study found that some patients had normal levels on repeat testing. Thus, molecular genetic testing remains the gold standard for confirmation and characterization within the spectrum.

What is the risk for family members of FMRD patients?

Heterozygous carriers, such as parents, may be at risk for HLRCC. This condition involves skin and uterine leiomyomas as well as renal cell carcinoma. Independent clinical evaluation for cancer risk is essential for these relatives, regardless of the child's specific variant.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ting SL et al. A Diagnostic Conundrum in Fumarase Deficiency: Expanding the Clinical and Genetic Spectrum in a Cohort of Pediatric and Adult Patients. Am J Med Genet A. 2026 Apr 12. doi: 10.1002/ajmg.a.70160. PMID: 41968386.